Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Rheumatology International
Published in: Rheumatology International 11/2009

01-09-2009 | Original Paper

Prognostic indicators related to death in patients with Pneumocystis pneumonia associated with collagen vascular diseases

Authors: Yoko Aoki, Masahiro Iwamoto, Yasuyuki Kamata, Takao Nagashima, Taku Yoshio, Hitoaki Okazaki, Seiji Minota

Published in: Rheumatology International | Issue 11/2009

Login to get access

Abstract

The objective of this study is to investigate the clinical markers of life-threatening Pneumocystis pneumonia (PCP) in patients with collagen vascular diseases (CVD). The patients who contracted Pneumocystis jeroveccii were retrospectively selected from our medical charts and conditions related to the patients’ death were reviewed. The findings indicated that lower levels of serum albumin and cholinesterase, increased alveolar–arterial oxygen gradient, intratracheal intubation, and necessity to treat in the intensive care unit were significantly related to deaths associated with PCP in CVD. A special attention should be paid to decreased serum albumin and cholinesterase as ominous predictors in PCP occurred in patients with CVD.
Literature
1.
2.
3.
Yasuoka A, Tachikawa N, Shimada K et al (1996) (1 → 3) β-d-glucan as a quantitative serological marker for Pneumocystis carinii pneumonia. Clin Diagn Lab Immunol 3:197–199PubMed
4.
Saito K, Nakayamada S, Nakano K et al (2004) Detection of Pneumocystis carinii by DNA amplication in patients with connective tissue diseases: re-evaluation of clinical features of P. carinii pneumonia in rheumatic diseases. Rheumatology 43:479–485. doi:10.​1093/​rheumatology/​keh071 PubMedCrossRef
5.
Limper AH, Offord KP, Smith TF et al (1989) Pneumocystis carinii pneumonia. Differences in lung parasite number and inflammation in patients with and without AIDS. Am Rev Respir Dis 140:1204–1209PubMed
6.
Ward MM, Donald F (1999) Pneumocystis carinii pneumonia in patients with connective tissue diseases. Arthritis Rheum 42:780–789. doi:10.1002/1529-0131(199904)42:4<780::AID-ANR23>3.0.CO;2-MPubMedCrossRef
7.
Godeau B, Coutant-Perronne V, Huong DLT et al (1994) Pneumocystis carinii pneumonia in the course of connective tissue disease: report of 34 cases. J Rheumatol 21:246–251PubMed
8.
9.
10.
Iwama A, Yoshida M, Miwa A et al (1993) Improved survival from fungaemia in patients with haematological malignancies: analysis of risk factors for death and usefulness of early antifungal therapy. Eur J Haematol 51:156–160PubMedCrossRef
11.
12.
Metadata
Title
Prognostic indicators related to death in patients with Pneumocystis pneumonia associated with collagen vascular diseases
Authors
Yoko Aoki
Masahiro Iwamoto
Yasuyuki Kamata
Takao Nagashima
Taku Yoshio
Hitoaki Okazaki
Seiji Minota
Publication date
01-09-2009
Publisher
Springer-Verlag
Published in
Rheumatology International / Issue 11/2009
Print ISSN: 0172-8172
Electronic ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-009-0857-z

Other articles of this Issue 11/2009

Rheumatology International 11/2009 Go to the issue

Original Paper

Management of hepatitis B reactivation in patients with lupus nephritis

Case Report

Fatal myocarditis in adult-onset Still disease with diffuse intravascular coagulation

Original Paper

HLA-Cw*06 class I region rather than MICA is associated with psoriatic arthritis in Czech population

Case Report

Lung parenchymal consolidation as an uncommon presentation and cause of delayed diagnosis in atypical Kawasaki syndrome

Original Paper

The clinical and genetical features of 124 children with Familial Mediterranean fever: experience of a single tertiary center

Letter to the editor

Treatment outcomes in patients with non-infectious aortic valvulitis undergoing aortic valve replacement: implication for the treatment of aortic valve involvement in Behcet’s disease
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits